COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
Rhea-AI Summary
COSCIENS Biopharma (OTCQB: CSCIF) filed a Rule 13e-3 Transaction Statement with the SEC on April 20, 2026 proposing a two-step Share Capital Amendment to reduce U.S. holders of record below 300 and seek suspension of Exchange Act reporting.
The plan consolidates 150 pre-consolidation shares into one, then splits 50-for-1; holders under 150 would receive US$1.60 per pre-consolidation share and be cashed out. The company estimates approximately US$1.9 million in annualized cost savings if SEC Reporting Suspension is allowed. Shareholder approval at the June 2026 meeting is planned.
Positive
- Estimated annualized cost savings of US$1.9 million
- Plan aims to reduce holders of record to fewer than 300 to enable Form 15 filing
- Company intends to remain listed on the TSX and quoted on OTCQB
Negative
- Share Capital Amendment would eliminate approximately 6.8% of issued shares
- Remaining shareholders would hold one-third of pre-transaction share counts post-amendment
- SEC could deny the SEC Reporting Suspension, leaving the company with ongoing reporting costs
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, ONTARIO, April 20, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced today that it has filed a Rule 13e-3 Transaction Statement (the “Transaction Statement”) with the U.S. Securities and Exchange Commission (the “SEC”).
As previously disclosed, as part of its overall cost savings initiative, the Company voluntarily delisted from the Nasdaq Capital Market effective September 5, 2025, as the first step in a broader strategy to seek to terminate or suspend its public reporting obligations under the U.S. Securities Exchange Act of 1934 (the “Exchange Act”). The Transaction Statement describes the Company’s proposal to, subject to the receipt of necessary regulatory and shareholder approvals, undertake a two-step transaction consisting of (i) a consolidation (the “Consolidation”) of the Company’s common shares on the basis of a one post-Consolidation common share for every 150 pre-Consolidation common shares, and (ii) an immediately subsequent share split of the common shares on the basis of 50 common shares for every one (1) post-Consolidation common share (the “Split”, and together with the Consolidation, the “Share Capital Amendment”).
Pursuant to the proposed Share Capital Amendment: (i) shareholders holding fewer than 150 pre-Consolidation common shares at the effective time, would cease to have any rights as a shareholder other than the right to be paid cash consideration equal to US
The primary purpose of the proposed Share Capital Amendment is to reduce the number of "holders of record" (as determined pursuant to Rule 12g5-1 under the Exchange Act) to fewer than 300, enabling the Company to file a Form 15 with the SEC to suspend its reporting obligations under the Exchange Act (the "SEC Reporting Suspension"), unless denied by the SEC. These obligations include the Company’s obligations to file and submit annual reports on Form 20-F and reports on Form 6-K. If the SEC Reporting Suspension is completed, the Company estimates annualized cost-savings on a go-forward basis of approximately US
The Share Capital Amendment is considered a "going-private transaction" under Rule 13e-3 of the Exchange Act; however, the Company expects the transaction will only result in the elimination of approximately
The Company intends to seek shareholder approval for the Share Capital Amendment at its annual meeting (the “Meeting”) to be held in June 2026. The announcement of the proposed Share Capital Amendment contained in this news release is not a solicitation of a proxy. Prior to the Meeting, the Company will mail a notice of meeting and a management information circular containing detailed information regarding the Meeting and the Share Capital Amendment. In the meantime, the Transaction Statement, together with the exhibits thereto, is available on the Company’s profile on SEDAR+ at www.sedarplus.com and on EDGAR at www.sec.gov/edgar.
About COSCIENS Biopharma Inc.
COSCIENS is a life science company focused on the development of natural, plant-based active ingredients, leveraging the Company’s proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients currently used in leading skincare brands worldwide. The Company’s common shares are listed on the TSX under the symbol “CSCI” and are listed and posted for trading on the OTCQB® Venture Market under the symbol “CSCIF”. For more information, please visit COSCIENS' website at www.cosciensbio.com.
Forward-Looking Statements
Certain statements in this news release, referred to herein as "forward-looking statements", constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and "forward- looking information" under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as "anticipate", "assume", "believe", "could", "expect", "forecast", "future", "goal", "guidance", "intend", "likely", "may", "would" or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward- looking statements include such words. Forward-looking statements in this news release include, but are not limited to, statements relating to the Company’s plans to seek to terminate or suspend its reporting obligations under applicable U.S. securities laws and expected cost savings as a result thereof; the ability of the Company to reduce the number of holders of record below 300; the Company’s expectation that it will remain subject to U.S. reporting obligations indefinitely in the event the Share Capital Amendment (or a similar transaction) is not completed, and the timing of the Company’s annual shareholder meeting.
These statements are based on current expectations and assumptions, including factors or assumptions factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from those expressed or implied by such forward-looking statements, including but not limited to the factors described in “Risks Relating to Us and Our Business” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of their dates. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.
Issuer Contact:
Peter H. Puccetti
Interim CEO and Chairman of the Board
pp@cosciensbio.com
Giuliano La Fratta
Chief Financial Officer
glafratta@cosciensbio.com
Investor Contact:
IR@cosciensbio.com
